BiomX Inc.
Symbol: PHGE (NYSE)
Company Description:
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
- Today's Open: $0.535
- Today's High: $0.534
- Today's Low: $0.501
- Today's Volume: 242.54K
- Yesterday Close: $0.52
- Yesterday High: $0.53
- Yesterday Low: $0.5
- Yesterday Volume: 192.40K
- Last Min Volume: 0
- Last Min High: $0.518
- Last Min Low: $0.517
- Last Min VWAP: $0
- Name: BiomX Inc.
- Website: https://www.biomx.com
- Listed Date: 2019-03-13
- Location: NESS ZIONA, L3
- Market Status: Active
- CIK Number: 0001739174
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $13.89M
- Round Lot: 100
- Outstanding Shares: 26.55M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-28 | ARS | View |
| 2025-08-28 | DEFA14A | View |
| 2025-08-28 | DEF 14A | View |
| 2025-08-19 | 8-K | View |
| 2025-08-15 | PRE 14A | View |
| 2025-08-13 | 424B5 | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-08-07 | SCHEDULE 13G/A | View |
| 2025-08-05 | SCHEDULE 13G | View |
| 2025-07-30 | 8-K | View |
| 2025-07-08 | 8-K | View |
| 2025-06-23 | SCHEDULE 13D/A | View |
| 2025-06-09 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-15 | 10-Q | View |
| 2025-05-15 | 8-K | View |
| 2025-05-08 | SCHEDULE 13G | View |